Skip to main content

Table 1 Baseline patient’s characteristics

From: Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Characteristics (N=54)

N° of patients (%)

Median age (range)

65 (43–80)

Median follow-up from 1st line, months (range)

26 (8–65)

Median follow-up from 2nd line, months (range)

13 (3–51)

Sex   Men

31 (57)

     Women

23 (43)

ECOG performance status

 

     0/1

36 (67)/18 (33)

Primary diagnosis

 

     Colon cancer

42 (78)

     Rectal cancer

12 (22)

Metastasis Site

 

     Single

41 (76)

     Multiple

13 (24)

KRAS status

 

     Wild type (%)

31 (57)

     Mutant Kras (%)

2 (4)

     Unknown

21 (39)